Presentations highlight efzofitimod’s potential for pulmonary sarcoidosis
Many people with moderate or severe pulmonary sarcoidosis — the target market for the investigational therapy efzofitimod — are highly burdened by the disease and are dependent on corticosteroids that can have serious side effects, according to real-world analyses. “New real-world evidence underscores the growing burden of patients…